Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tyrosine kinase inhibitors
Biotech
Alumis hits stride as TYK2 inhibitor improves psoriasis in ph. 2
A couple days after closing a $259 million series C, Alumis is back, this time with phase 2 psoriasis data in hand.
Gabrielle Masson
Mar 9, 2024 12:00pm
Blueprint drops lung cancer programs after seeing early data
Jan 9, 2024 9:22am
Safety signal sinks Theseus' cancer program—and its share price
Jul 14, 2023 7:20am
Inhibikase stock sinks on FDA clinical hold of Parkinson's drug
Nov 7, 2022 9:25am
BMS, Nektar end $3.6B I-O program after 2 more late-stage flops
Apr 15, 2022 6:55am
Avistone nabs $200M cancer platform funding drive
Dec 8, 2021 7:00am
